302, 6 Butler Street

Camberwell, VIC, 3124 Australia


October 26, 2018




Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549


Re: Propanc Biopharma, Inc.
  Registration Statement on Form S-1
  File No. 333-227877


Ladies and Gentleman:


Pursuant to Rule 461 under the Securities Act of 1933, as amended, Propanc Biopharma, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated so that it will become effective at 10:00 A.M. Eastern Time on Tuesday, October 30, 2018, or as soon as practicable thereafter.


We request that we be notified of such effectiveness by a telephone call to Jonathan Shechter of Foley Shechter LLP at (212) 335-0465, or in his absence Sasha Ablovatskiy of Foley Shechter LLP at (212) 335-0466. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of such Registration Statement be sent to Foley Shechter LLP, attention: Jonathan Shechter, via facsimile at (917) 688-4092.


  By: /s/ James Nathanielsz
  Name:  James Nathanielsz
  Title: Chief Executive Officer and Chief Financial Officer


Cc: Jonathan Shechter, Foley Shechter LLP
  Sasha Ablovatskiy, Foley Shechter LLP